Drug Development
Insulin sensitizer MBX-102/JNJ-39659100 reduces inflammation in preclinical diabetes models
Published in Diabetes Week, February 12th, 2007
Metabolex investigators, presenting at the Keystone Symposium in Keystone, Colorado, compared the effect of MBX-102/JNJ-39659100, rosiglitazone and a vehicle treatment. MBX-102/JNJ-39659100 was previously referred to as metaglidasen.
Both mice and rats treated with either active compound demonstrated substantially reduced inflammation...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2007-02-12)
More Articles from Diabetes Week
- Atherosclerosis Risk Factors
Study results from Johns Hopkins University, Department of Epidemiology in the area of atherosclerosis risk factors published - Depression Risk Factors
Reports from Norwegian University of Science and Technology advance knowledge in depression risk factors - Depression Therapy
Researchers from University of Louisville discuss findings in depression therapy - Diabetic Retinopathy Cell Biology
Studies from King's College London yield new data on diabetic retinopathy cell biology - Gene Therapy
New gene therapy study findings have been reported by researchers at Genzyme Corporation, Department of Molecular Biology - Heart Attack
Scientists at Chang Gung Memorial Hospital, Department of Pathology target heart attack - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
